0 105

Cited 7 times in

Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status

Authors
 Chan Woo Wee  ;  Eunji Kim  ;  Nalee Kim  ;  In Ah Kim  ;  Tae Min Kim  ;  Yu Jung Kim  ;  Chul-Kee Park  ;  Jin Wook Kim  ;  Chae-Yong Kim  ;  Seung Hong Choi  ;  Jae Hyoung Kim  ;  Sung-Hye Park  ;  Gheeyoung Choe  ;  Soon-Tae Lee  ;  Jong Hee Chang  ;  Se Hoon Kim  ;  Chang-Ok Suh  ;  Il Han Kim 
Citation
 Radiotherapy and Oncology, Vol.123 : 106-111, 2017 
Journal Title
 Radiotherapy and Oncology 
ISSN
 0167-8140 
Issue Date
2017
MeSH
Adult ; Aged ; Brain Neoplasms/drug therapy ; Brain Neoplasms/genetics* ; DNA Methylation* ; DNA Modification Methylases/genetics* ; DNA Repair Enzymes/genetics* ; Dacarbazine/analogs & derivatives ; Dacarbazine/therapeutic use ; Female ; Glioblastoma/drug therapy ; Glioblastoma/genetics* ; Humans ; Isocitrate Dehydrogenase/genetics* ; Male ; Middle Aged ; Mutation* ; Promoter Regions, Genetic* ; Tumor Suppressor Proteins/genetics*
Keywords
Glioblastoma ; Isocitrate dehydrogenase ; MGMT ; Recursive partitioning analysis ; Temozolomide
Abstract
BACKGROUND AND PURPOSE: To refine the recursive partitioning analysis (RPA) classification for glioblastoma incorporating the MGMT methylation and IDH1 mutation status. METHODS AND MATERIALS: Three-hundred forty patients were treated with radiotherapy plus concurrent and adjuvant temozolomide in three tertiary-referral hospitals. MGMT methylation and IDH1 mutation status were available in all patients. Methylation of the MGMT (MGMTmeth) and mutation of IDH1 (IDH1mut) were observed in 42.4% and 6.2% of the patients, respectively. RESULTS: The median follow-up for survivors and all patients was 33.2 and 20.5months, respectively. The median survival (MS) was 23.6months. RPA was performed on behalf of the results of the Cox proportional hazards model. MGMT methylation generated the initial partition (MGMTmeth vs. MGMTunmeth) in the RPA. Three final RPA classes were identified; class I=MGMTmeth/IDH1mut or MGMTmeth/IDH1wt/GTR/KPS≥90 (MS, 67.2months); class II=MGMTmeth/IDH1wt/GTR/KPS<90, MGMTmeth/IDH1wt/residual disease, MGMTunmeth/age<50, or MGMTunmeth/age≥50/GTR (MS, 24.0months); class III=MGMTunmeth/age≥50/residual disease (MS, 15.2months). CONCLUSIONS: A novel RPA classification for glioblastoma was formulated highlighting the impact of MGMTmeth and IDH1mut in the temozolomide era. This model integrating pertinent molecular information can be used effectively for the patient stratification in future clinical trials. An external validation is ongoing.
Full Text
http://www.sciencedirect.com/science/article/pii/S0167814017300919
DOI
10.1016/j.radonc.2017.02.014
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
Yonsei Authors
김세훈(Kim, Se Hoon) ORCID logo https://orcid.org/0000-0001-7516-7372
서창옥(Suh, Chang Ok)
장종희(Chang, Jong Hee)
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/153875
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse